FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular, to a monoclonal antibody or an antigen-binding fragment thereof, capable of specifically binding to human alpha-synuclein, as well as to an agent, a composition, and a conjugate containing said antibody or fragment. Also disclosed are a nucleic acid encoding said antibody or a fragment thereof.
EFFECT: invention is effective for treating synucleopathy, for identifying the presence of alpha-synuclein in the brain of the subject, as well as for measuring the amount of alpha-synuclein in the brain of the subject.
56 cl, 27 dwg, 4 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST ALPHA SYNUCLEIN | 2018 |
|
RU2787039C2 |
| ANTIBODIES | 2018 |
|
RU2798399C2 |
| MONOCLONAL ANTIBODIES TO ALPHA-SYNUCLEIN FOR PREVENTING TAU-PROTEIN AGGREGATION | 2017 |
|
RU2760334C2 |
| COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2804815C2 |
| STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A (ClfA) ANTIBODY | 2019 |
|
RU2818805C2 |
| ANTIBODY AGAINST HUMAN INTERLEUKIN-4 ALPHA RECEPTOR, METHOD OF ITS PREPARATION AND ITS APPLICATION | 2021 |
|
RU2807060C1 |
| ANTIBODIES B7-H4 AND METHODS FOR THEIR APPLICATION | 2019 |
|
RU2809243C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| HUMANIZED ANTIBODIES THAT RECOGNIZE ALPHA-SYNUCLEINE | 2012 |
|
RU2743738C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
